Clinical utility shown for Avantís mTOR assay
September 2017

GAITHERSBURG, Md.—Independent published data was published this quarter validating Avant Diagnostics Inc.’s proprietary Theralink mTOR phosphoprotein assay in delineating the estrogen receptor positive (ER+) breast cancer (BC) population by mTOR activation status. The data showed that ER+ BC patients with tumors that have a highly activated mTOR pathway were likely to have treatment resistance when treated with anti-endocrine therapies, while those with low levels of mTOR pathway activation are more likely to respond to such therapies.
Dr. Emanuel Petricoin, co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University, commented that “The data provides a strong rationale for physicians to seek out mTOR pathway activation status as measured by protein phosphorylation of specific mTOR kinase substrates as part of the standard biomarker profiling paradigm in this patient population.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.